Shares of Incyte Corp. INCY slipped 1.62% to $65.74 Friday, on what proved to be an all-around mixed trading session for the ...

Incyte Corp (INCY) stock saw a modest uptick, ending the day at $66.82 which represents a slight increase of $1.65 or 2.53% from the prior close of $65.17. The stock opened at $66.22 and touched a low ...

Is Syndax Pharmaceuticals, Inc. a buy after the recent stock decline? Analysts support, upcoming approvals, but expect a ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and ...

US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of ...

Shares of Incyte Corp. INCY slid 1.90% to $65.17 Wednesday, on what proved to be an all-around grim trading session for the ...

Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...

Fintel reports that on September 18, 2024, Truist Securities downgraded their outlook for Incyte (NasdaqGS:INCY) from Buy to ...

Stocks are lower Wednesday, the S&P 500 both on track to snap a seven-day winning streak as investors await the end of the Fed's two-day meeting ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

周三，Truist Securities调整了对Incyte Corporation (NASDAQ:INCY)的立场，将该股票从买入下调至持有，同时将目标价从83美元下调至74美元。这一决定是因为这家生物制药公司即将面临其旗舰产品Jakafi的专利到期。 在最近的一份声明中，Truist Securities承认Incyte成功推出了Opzelura并努力使其管线多样化。尽管如此，该公司表示担心 ...